Skip to content

Evaluation of the effectiveness of black halilah and fennel powder in clinical symptoms of patients with coronavirus.

Evaluation of the effect of feneel_terminalia chebula (FT®)powder on clinical and paraclinical symptoms in patients with Covid 19.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150819023685N3
Enrollment
70
Registered
2021-08-16
Start date
2021-03-21
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19. Covid19

Interventions

Intervention 1: Intervention group: TherapIntervention group: Treatment protocol of the Ministry of Health + FT® powder, which contains a combination of black halibut powder and fennel with a natural
In this group, drugs such as remdesivir, corticosteroids, etc., which are commonly prescribed by doctors for patients with Quid 19, are used.

Sponsors

Ghoum University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inpatients diagnosed with Covid 19. Patients with Covid 19 who wish to participate in the study No serious heart disease, liver, kidney, blood pressure above 160 mm Hg Patients who do not receive insulin Non-pregnancy in women. A maximum of 72 hours have passed since the beginning of the patient's hospitalization.

Exclusion criteria

Exclusion criteria: 1. Dissatisfaction with continuing treatment. 2. Need to receive medical services in the intensive care unit.

Design outcomes

Primary

MeasureTime frame
Days of hospitalization. Timepoint: Daily. Method of measurement: View patient records.;Clinical signs. Timepoint: Before treatment and 2, 4, 7 days of treatment. Method of measurement: The severity of each of the patient's clinical symptoms is measured based on the visual analog scale in patients.;Vital Signs. Timepoint: During hospitalization on a daily basis. Method of measurement: Monitoring device.

Secondary

MeasureTime frame
Mortality. Timepoint: Daily patient follow-up. Method of measurement: View patient records.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Mehdi Fallahpour Khoshdel

Mashhad University of Medical Sciences

fallahmohammad313@gmail.com+98 51 3180 1100

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026